Table 3.
. Patient and tumor characteristics in UFD and MFD childhood and adolescent lobectomy patients, n = 66
| Variable | UFD n = 50 | % | MFD n = 16 | % | P valueb |
|---|---|---|---|---|---|
| Age (y) | 18.4 (15.2, 20.2)a | — | 19.0 (17.6, 21.0)a | — | .2 |
| Sex | |||||
| Male | 9 | 18 | 2 | 13 | >.9 |
| Female | 41 | 82 | 14 | 88 | |
| pT stage | |||||
| T1 | 36 | 72 | 12 | 80 | .595 |
| T2 | 12 | 24 | 2 | 13 | |
| T3 | 2 | 4 | 1 | 6.7 | |
| T4 | 0 | 0 | |||
| pN stage | |||||
| N0 | 39 | 78 | 9 | 56 | .017* |
| N1a | 10 | 20 | 3 | 19 | |
| N1b | 1 | 2.0 | 4 | 25 | |
| M stage | |||||
| M0 | 50 | 100 | 16 | 100 | NA |
| M1 | 0 | 0 | |||
| ATA pediatric risk | |||||
| Low | 46 | 92 | 12 | 75 | .023* |
| Intermediate | 3 | 6.0 | 0 | ||
| High | 1 | 2.0 | 4 | 25 | |
| PTC subtype | |||||
| Classical | 26 | 53 | 8 | 80 | .5 |
| Follicular | 15 | 31 | 1 | 10 | |
| Tall cell | 7 | 14 | 1 | 10 | |
| Solid/trabecular | 1 | 2.0 | 0 | ||
| LVI | |||||
| No | 46 | 92 | 11 | 92 | >.9 |
| Yes | 4 | 8.0 | 1 | 8.3 | |
| Microscopic ETE | |||||
| No | 45 | 90 | 11 | 73 | .2 |
| Yes | 5 | 10 | 4 | 27 | |
| Margins | |||||
| Negative | 46 | 98 | 10 | 91 | .3 |
| Positive | 1 | 2.1 | 1 | 9.1 | |
Missing observations excluded from counts. Percents rounded to 2 significant figures.
Abbreviations: ATA, American Thyroid Association; ETE, extrathyroidal extension; LVI, lymphovascular invasion; M, metastasis; MFD, multifocal disease; pN, pathological node; pT, pathological tumor; PTC, papillary thyroid carcinoma; UFD, unifocal disease.
a Median (interquartile range); n (%).
b Wilcoxon rank sum test; Pearson χ2 test; Fisher exact test.
*Denotes significant P value.